Myriad Genetics (MYGN) FDA Approvals $4.40 +0.09 (+2.09%) Closing price 06/3/2026 04:00 PM EasternExtended Trading$4.28 -0.13 (-2.84%) As of 06/3/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Myriad Genetics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Myriad Genetics (MYGN). Over the past two years, Myriad Genetics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as niraparib. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Niraparib FDA Regulatory Events Niraparib is a drug developed by Myriad Genetics for the following indication: patients with advanced ovarian cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. FDA approved - March 17,2026Fda Approved Drug: niraparibAnnounced Date: March 17, 2026Indication: patients with advanced ovarian cancer.AnnouncementMyriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.AI SummaryMyriad Genetics announced that the U.S. Food and Drug Administration has approved the MyChoice® CDx Test as the companion diagnostic for Zejula® (niraparib), GSK’s PARP inhibitor, for patients with advanced ovarian cancer. The approval allows MyChoice CDx to be used to identify patients whose tumors show homologous recombination deficiency (HRD), helping clinicians determine who is likely to benefit from Zejula treatment. Myriad said the decision highlights its leadership in ovarian cancer diagnostics and the clinical value of broad HRD testing. Nearly half of patients with advanced ovarian cancer have HRD-positive tumors, so identifying these patients is key to choosing appropriate PARP inhibitor therapy and personalizing treatment plans. By providing robust genomic information, MyChoice CDx aims to guide treatment decisions and improve matching of patients to targeted therapy.Read Announcement Myriad Genetics FDA Events - Frequently Asked Questions Has Myriad Genetics received FDA approval? As of now, Myriad Genetics (MYGN) has not received any FDA approvals for its therapy in the last two years. What drugs has Myriad Genetics submitted to the FDA? In the past two years, Myriad Genetics (MYGN) has reported FDA regulatory activity for niraparib. What is the most recent FDA event for Myriad Genetics? The most recent FDA-related event for Myriad Genetics occurred on March 17, 2026, involving niraparib. The update was categorized as "FDA approved," with the company reporting: "Myriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer." What conditions do Myriad Genetics' current drugs treat? Currently, Myriad Genetics has one therapy (niraparib) targeting the following condition: patients with advanced ovarian cancer.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events argenex FDA EventsAxsome Therapeutics FDA EventsBiogen FDA EventsCabaletta Bio FDA EventsDyne Therapeutics FDA EventsFibroBiologics FDA EventsIDEAYA Biosciences FDA EventsLexicon Pharmaceuticals FDA EventsMannKind FDA EventsInsulet FDA EventsTG Therapeutics FDA EventsTenaya Therapeutics FDA EventsJohnson & Johnson FDA EventsCandel Therapeutics FDA EventsCelcuity FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Zenas BioPharma FDA Events MannKind FDA Events Lexicon Pharmaceuticals FDA Events OPKO Health FDA Events Geron FDA Events Ironwood Pharmaceuticals FDA Events Crescent Biopharma FDA Events Rigel Pharmaceuticals FDA Events Achieve Life Sciences FDA Events Emergent Biosolutions FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:MYGN last updated on 3/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA approved - March 17,2026Fda Approved Drug: niraparibAnnounced Date: March 17, 2026Indication: patients with advanced ovarian cancer.AnnouncementMyriad Genetics, Inc announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.AI SummaryMyriad Genetics announced that the U.S. Food and Drug Administration has approved the MyChoice® CDx Test as the companion diagnostic for Zejula® (niraparib), GSK’s PARP inhibitor, for patients with advanced ovarian cancer. The approval allows MyChoice CDx to be used to identify patients whose tumors show homologous recombination deficiency (HRD), helping clinicians determine who is likely to benefit from Zejula treatment. Myriad said the decision highlights its leadership in ovarian cancer diagnostics and the clinical value of broad HRD testing. Nearly half of patients with advanced ovarian cancer have HRD-positive tumors, so identifying these patients is key to choosing appropriate PARP inhibitor therapy and personalizing treatment plans. By providing robust genomic information, MyChoice CDx aims to guide treatment decisions and improve matching of patients to targeted therapy.Read Announcement
